Loading...
Market
Story
Merck's HPV Vaccine for Men Approved by China’s Drug Regulator for Ages 9-26, First of Its Kind
Jan 8, 2025, 04:50 AM
China's drug regulator has approved Merck's human papillomavirus (HPV) vaccine for men, marking a significant expansion for the U.S. pharmaceutical company in an emerging market. The vaccine is specifically authorized for males aged 9 to 26 and is the first of its kind in China. This approval comes after a decline in demand among women for the vaccine, which had previously surged. Merck's announcement, made via its Chinese subsidiary, MSD, highlights the potential for growth in a new demographic following the approval by China's medical products administration.
View original story
Similar markets
Revised guidelines • 25%
Increased studies • 25%
No change • 25%
Other actions • 25%
No • 50%
Yes • 50%
No changes recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
Issue new safety guidelines • 25%
Conduct further studies • 25%
Other actions • 25%
No action taken • 25%
Positive impact • 25%
Significant negative impact • 25%
Minor negative impact • 25%
No impact • 25%
Significant issues found • 25%
No issues found • 25%
Undetermined • 25%
Minor issues found • 25%